James Quigley
Stock Analyst at Goldman Sachs
(1.19)
# 3,724
Out of 5,030 analysts
23
Total ratings
50%
Success rate
-4.26%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Downgrades: Sell | $119 → $118 | $131.43 | -10.22% | 2 | Sep 12, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $59.83 | +32.04% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $50.62 | +28.41% | 1 | Mar 21, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $9.65 | +8.81% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $34.51 | +15.91% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.88 | +312.37% | 3 | Jun 23, 2023 |
Novartis AG
Sep 12, 2025
Downgrades: Sell
Price Target: $119 → $118
Current: $131.43
Upside: -10.22%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $59.83
Upside: +32.04%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $50.62
Upside: +28.41%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $9.65
Upside: +8.81%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $34.51
Upside: +15.91%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.88
Upside: +312.37%